Clear Creek Financial Management LLC Sells 561 Shares of DexCom, Inc. $DXCM

Clear Creek Financial Management LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 7.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,451 shares of the medical device company’s stock after selling 561 shares during the period. Clear Creek Financial Management LLC’s holdings in DexCom were worth $650,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Golden State Wealth Management LLC lifted its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom in the first quarter worth about $27,000. Anderson Financial Strategies LLC purchased a new stake in shares of DexCom in the first quarter worth about $37,000. Alpine Bank Wealth Management purchased a new stake in shares of DexCom in the first quarter worth about $40,000. Finally, Private Trust Co. NA raised its position in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 335 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $65.12 on Friday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The business has a 50 day simple moving average of $74.42 and a 200-day simple moving average of $77.62. The firm has a market capitalization of $25.54 billion, a PE ratio of 45.22, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a report on Wednesday. William Blair raised DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Truist Financial began coverage on DexCom in a research report on Monday, June 16th. They set a “buy” rating and a $102.00 target price on the stock. The Goldman Sachs Group decreased their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Finally, Barclays increased their price objective on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $97.42.

Insider Buying and Selling

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock worth $564,733 over the last ninety days. Insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.